MedTrace Logo

Lingdancao Granules in the Treatment of Seasonal Influenza

NCT02662426 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2016-02-17

No results posted yet for this study

Summary

Name of study:

Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study about Lingdancao Granules in the Treatment of Seasonal Influenza

Objective:

Preliminary evaluation on the efficacy and safety of Lingdancao granules in the treatment of seasonal influenza

Design:

Multicenter, randomized, double-blind, double parallel analogy, positive drug and placebo controlled trial

Case number:

This test is expected to be included in 318 cases of 14-65 (≥14 or ≤65) ages of subjects. Qualified participants are randomly divided into experimental drug group (Lingdancao granules group), positive control group (oseltamivir phosphate group) and placebo group, 106 cases in each.

Conditions

Interventions

DRUG

Lingdancao granules

4 packs per time (3g/pack), three times per day

DRUG

analogous oseltamivir phosphate capsule

1 capsule per time, twice per day

DRUG

Oseltamivir phosphate capsule

1 capsule per time (75mg), twice per day

DRUG

analogous Lingdancao granules

4 packs per time, three times per day

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Xinhua Wang, PhD · The 1st Affiliated Hospital of Guangzhou Medical University

  • Hongixa Ma, PhD · The 1st Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-11-30
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02662426 on ClinicalTrials.gov